The authors reply

We thank Dufour and Devresse 1 Dufour I. Devresse A. Information regarding polypill treatment is lacking. Kidney Int. 2023; 103: 1201 Google Scholar for their interest in our report. 2 Mann J.F.E. Joseph P. Gao P. et al. TIPS-3 investigators. Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease. Kidney Int. 2023; 103: 403-410 Abstract Full Text Full Text PDF Scopus (0) Google Scholar Indeed, the International Polycap Study-3 trial used a 3-way factorial design to examine the effects of aspirin, of a polypill (containing atenolol, ramipril, simvastatin, and hydrochlorothiazide), and of vitamin D versus respective placebo. In our present report, we address the effects of aspirin versus placebo in those with an estimated glomerular filtration rate of <60 ml/min per 1.73 m2. No interaction of polypill (P = 0.9853) or vitamin D (P = 0.8345) with aspirin’s effects versus placebo was found (see also Methods section). We also investigated the effects of the polypill in those with an estimated glomerular filtration rate of <60 ml/min per 1.73 m2. Those data are presently under review. Effects of aspirin on cardiovascular outcomes in patients with chronic kidney diseaseKidney InternationalVol. 103Issue 2PreviewPatients with chronic kidney disease (CKD) carry a high cardiovascular (CV) risk. Since whether this risk is reduced by aspirin is unclear, we examined if the effect of aspirin on cardiovascular outcomes varied by baseline kidney function in a primary cardiovascular disease prevention trial. The International Polycap Study-3 (TIPS-3) trial had randomized people without previous cardiovascular disease to aspirin (75 mg daily) or placebo. We now examined aspirin versus placebo on cardiovascular events in participants grouped by estimated glomerular filtration rate (eGFR), using a threshold of 60 ml/min/1.73 m2, and by using tertiles of eGFR. Full-Text PDF Information regarding polypill treatment is lackingKidney InternationalVol. 103Issue 6PreviewWe read with interest the recently published clinical trial of Mann et al.,1 which is a subgroup analysis of the International Polycap Study-3 (TIPS-3) trial.2 The TIPS-3 trial was a double-blinded, 2-by-2-by-2 factorial randomized controlled trial, including participants, without history of cardiovascular disease, with intermediate or high cardiovascular risk. Interventions were daily polypill (containing simvastatin, atenolol, hydrochlorothiazide, and ramipril) versus placebo; aspirin, 75 mg/d, versus placebo; and vitamin D versus placebo. Full-Text PDF